Glozier N
Psychiatry, Sydney Medical School, https://ror.org/0384j8v12University of Sydney, Australia.
ArticleKetamine
Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study.
ArticleKetamine
Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).
ArticlePsilocybin
A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia.
ArticleKetamine
Implementation of a ketamine programme for treatment-resistant depression in the public health system: Lessons from the first Australian public hospital clinic.
ArticleKetamine
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.
ArticleKetamine
Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression.
ArticleKetamine
A systematic review of the print media representation of ketamine treatments for psychiatric disorders.
ArticleMDMA